Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0600142 (hot flushes)
 1,242 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Vasomotor symptoms such as hot flushes and profuse sweating have been described after bilateral orchiectomy. We evaluated 26 patients who had undergone bilateral orchiectomy for prostatic carcinoma to determine the incidence of vasomotor symptoms and the efficacy of low-dose diethylstilbestrol (DES) in the treatment of those symptoms. Measurements of serum follicle-stimulating hormone (FSH), luteinizing hormone (LH), and testosterone were performed to look for endocrine patterns which may be related to the presence of vasomotor symptoms. Fourteen patients (54%) reported the presence of vasomotor symptoms beginning one to four weeks after surgery. These patients were treated with DES or placebo in a double-blind crossover trial. The frequency and severity of hot flushes were significantly reduced during the time DES was given. This was accomplished with a low dose of 1 mg daily of DES which avoids the cardiovascular complications of higher doses. We found no correlation between the presence, severity, or frequency of hot flushes and serum gonadotropin or testosterone concentrations.
 ...
PMID:Diethylstilbestrol in treatment of postorchiectomy vasomotor symptoms and its relationship with serum follicle-stimulating hormone, luteinizing hormone, and testosterone. 173

The authors contend that conclusions regarding the existence of a menopausal syndrome based on clinical trials with oestrogen therapy cannot be generalized to the general population. As an alternative strategy for investigating the nature of the menopausal syndrome the authors performed a factor analysis of the results from a symptom checklist. The list was included in a postal questionnaire sent to a representative sample of 2349 women aged between 45 and 55 years residing in the city of Oslo, Norway. A varimax, rotated five-factor solution yielded the best result both theoretically and empirically. The five factors were labelled as vague somatic complaints, nervousness, mood lability, vasomotor complaints and urogenital complaints. Five variables were constructed on the basis of the factor scores. One-way analysis of variance showed that vasomotor complaints associated with excessive sweating, hot flushes and vaginal dryness, constituted the only variable significantly related to menopausal development. The latter was measured according to time elapsed since the last menstrual period.
 ...
PMID:The menopausal syndrome: a factor analytic replication. 194 27

A total of 2349 Norwegian women aged 45-55 years, were investigated using postal questionnaires. Associations between menopausal development, psychosocial factors and climacteric complaints were analyzed. Factor analysis of 24 climacteric complaints identified five factors (vague somatic complaints, nervous complaints, mood lability, vasomotor and urogenital complaints) which were analyzed in relation to stage of menopausal development and a number of psychosocial variables. Five types of variable contributed to the variance in the five previously identified factors, viz. style of reacting to menstruation earlier in life, mother's climacteric complaints, negative expectations regarding the menopause, social network, sociodemographic factors, and chronological age. Menopausal development played a modest role in explaining the variance in all except vasomotor complaints, the latter being associated with current cigarette smoking. Traditional sex-role identification was associated with nervous complaints. The authors conclude that hot flushes, excessive sweating and vaginal dryness are the only complaints clearly attributable to menopausal development.
 ...
PMID:Psychosocial determinants of climacteric complaints. 194 28

Twenty-four women with large, myomatous uteri, measuring between 218.7 and 2,920 cm3 were treated with gestrinone, a tri-enic steroid with antiestrogen and antiprogesterone properties. In order to saturate the receptors of the large myomata, the doses used to treat these women were twice the recommended dosage of 2.5 mg, 3 times weekly, used to treat smaller tumors. The treatment lasted 6 months to 1 year. In all cases there was a reduction in uterine volume. In the 24 patients, the mean uterine volume of 724.9 cm3 on admission decreased to 450.73 cm3 at 6 months. For 14 patients treated for a full year, the mean uterine volume of 689.73 cm3 decreased to 329.22 cm3. Menstruation was suppressed in all patients by the end of the 2nd month of treatment. Episodic bleeding occurred in 6 patients but in only 1 did this last longer than 1 week. Other symptoms such as pelvic discomfort and dysuria disappeared or were significantly alleviated by the 2nd month of treatment. Side effects included seborrhea, acne, nervousness, myalgia and arthraglia, hoarseness and mild hirsutism but all these symptoms were promptly reversed following discontinuation. The mean increase in weight was 3.4 kg in 6 months. No menopausal symptoms such as hot flushes and depression developed during this trial. Six patients complained of excessive sweating. Blood glucose creatinine, blood urea nitrogen, alkaline phosphatase, pyruvic and glutamic transaminases remained within the normal range.
 ...
PMID:Treatment of large fibroids with high doses of gestrinone. 222 12

As a result of the general lack of information about the menopause in Nigeria this study was conducted to determine the prevalence of climacteric symptoms in a cohort of healthy perimenopausal women and also to evaluate the hormonal and biochemical profile of the subjects. Seventeen menopausal and 19 premenopausal women aged 40 years or more were interviewed and had venepuncture and collection of 24-h urine samples. Plasma from the blood samples was used for the assay of LH, FSH, progesterone, 17 beta-oestradiol, calcium and cholesterol while urinary calcium was determined from the 24-h urine samples. The data revealed a significant difference in the prevalence of the symptoms of vasomotor instability (hot flushes, palpitations and excessive sweating) among the menopausal group when compared with the premenopausal group. Furthermore, plasma gonadotrophin levels (LH and FSH) were significantly elevated while plasma oestradiol and progesterone levels were lower in the menopausal women than in the premenopausal group. With regards to the biochemical indices evaluated, only 24-h urinary calcium levels were found to be significantly different for the two groups, with higher levels in the menopausal women. The significance of these findings and the need for adequate screening and treatment of selected menopausal women are discussed.
 ...
PMID:Clinical, hormonal and biochemical features of menopausal women in Ibadan, Nigeria. 255 55

Two hundred perimenopausal women who suffered from several symptoms and signs of menopause participated in this 3-year prospective study. Because they were still menstruating more or less regularly, these women were afraid of becoming pregnant and asked for contraception as well as hormone replacement therapy (HRT). Therefore the HRT chosen was a low dose triphasic oral contraceptive. The patient population was divided into two groups; one group (100 women) took the triphasic contraceptive as HRT and the other group served as controls (100 women). During the three years of this study this form of HRT was demonstrated to prevent conception and bone-mass loss, combat vaginal dryness and sexual disturbances, eliminate hot flushes and profuse sweating, correct breast atrophy, and prevent or improve psycho-functional disturbances, such as depressive mood, loss of concentration, insomnia, nervousness, palpitations and fatigue. It was concluded, based on the results of this study, that the triphasic oral contraceptive is the treatment of choice in the prevention and treatment of menopausal symptoms during the perimenopause--when contraception is still required.
 ...
PMID:Hormone replacement therapy in perimenopausal women with a triphasic contraceptive compound: a three-year prospective study. 286 16

The vasomotor hot flushes and increased perspiration symptomatic of the menopausal period reflect the adaptation of the body to the lowering of its preset basal temperature resulting from the interference of various central neurotransmitters of suprahypothalamohypophyseal origin. The present double-blind study was conducted to test the efficacy of veralipride, a synthetic antidopaminergic molecule, in eliminating the symptoms of menopause in 50 patients. Results indicated a total elimination of both hot flushes and excessive perspiration in 63% to 80% of the patients treated. The beneficial effects persisted up to 3 months of follow-up. Veralipride significantly increased dehydroepiandrosterone sulfate and estradiol levels. High values of prolactin were found, and some patients showed slight breast discharge; these changes disappeared 48 hours after the drug was stopped.
 ...
PMID:Veralipride: alternative antidopaminergic treatment for menopausal symptoms. 296 34

In a group of 20 menopausal women 45-78 years old (mean age 62.4), with typical symptoms such as dryness of the vagina, urinary disturbances, "mental" symptoms, or vasomotor disturbances, treated with topical vaginal estrogen cream, we examined the glucose tolerance, as expressed by Gycohemoglobin (HbA1c) and GTT. Estrogen, well absorbed by the vaginal epithelium gives rise to the HbA1c from a mean of 6.4% to 14.78% (P less than 0.0001). The GTT too shows a glucose intolerance, but never a frank diabetic picture. In four cases in which the cardinal symptoms were vasomotor disturbances (hot flushes, profuse sweating) the addition of oral clonidine hydrochlorate (Clonirit) to the vaginal estrogen cream, leads to the relief of symptoms. The Glycohemoglobin test is fast, inexpensive and easy to perform in every laboratory, giving the possibility of discovering an unknown or borderline diabetes.
 ...
PMID:Increase in glycosylated hemoglobin (HbA1c) in menopausal women treated with vaginal estrogen cream. 406 6

Orchiectomy is a frequently performed androgen ablative therapy in men with prostatic cancer. Sudden withdrawal of sex steroids in men can lead to troublesome menopausal symptoms such as hot flushes (HF) and profuse sweating. In the past, HF in men have received little attention and therapeutic options are not widely known. HF are a side effect of orchiectomy and other androgen ablative therapies and can no longer be neglected. The considerable decrease in quality of life caused by HF is particularly hard on patients who are dependent on palliative treatment. Because most patients will seek palliation, it is important that medical practitioners be made aware of the etiology and treatment of HF. In this article the frequency and intensity of HF in 32 patients were studied and present-day treatment options are summarized.
 ...
PMID:Post-orchiectomy hot flushes. 795 65

Menopausal hot flushes are accompanied by profuse sweating, decreased skin resistance, modest tachycardia and cutaneous vasodilation. With the exception of the last effect, these events are consistent with an abrupt increase in sympathetic outflow. Blood flow in the human finger is controlled through sympathetic vasoconstricting nerves, and increased sympathetic activation results in digital vasoconstriction. We therefore sought to determine if digital vasodilation during hot flushes was mediated through efferent sympathetic nerves. Bilateral finger temperature and blood flow were recorded after the digital nerves on one hand had been blocked with a local injection of lidocaine. The effectiveness of the nerve blocks was verified by a reflex vasoconstriction test. Hot flushes were objectively defined using skin conductance responses recorded from the sternum. Fifteen hot flushes occurred in 8 women. Significant elevations in finger temperature and blood flow occurred during the flushes, in nerve-blocked and intact fingers. These findings suggest that digital vasodilation during hot flushes is due to a circulating vasodilating substance.
 ...
PMID:Nonneural mediation of digital vasodilation during menopausal hot flushes. 800 77


1 2 Next >>